A 38-year-old woman from rural India presents for cervical cancer screening. Her previous Pap smear 3 years ago was normal. All of the following are appropriate management steps for abnormal cervical cytology findings EXCEPT:

Explanation

## Management of Abnormal Cervical Cytology: Triage and Colposcopy ### Cytology-Based Triage Algorithm **Key Point:** The Bethesda System 2014 classifies cervical cytology into categories, each with specific management pathways. HPV reflex testing guides triage for ASC-US and LSIL; HSIL bypasses HPV testing and proceeds directly to colposcopy. ### Correct Management Pathways | Cytology Finding | HPV Status | Management | |---|---|---| | ASC-US | Positive | Colposcopy with directed biopsy | | ASC-US | Negative | Routine screening (3 years) | | LSIL | Positive | Colposcopy | | LSIL | Negative | Repeat cytology at 12 months | | HSIL | Any | Immediate colposcopy (no HPV needed) | | AGC | Any | Colposcopy + endocervical curettage | | SCC (invasive) | Any | Staging and treatment, NOT biopsy | **High-Yield:** ASC-US with positive HPV reflex → colposcopy. LSIL with negative HPV → repeat cytology (not colposcopy) — this is a key low-risk pathway. ### Why Option 4 Is Wrong **Warning:** Cytology showing invasive squamous cell carcinoma (SCC) is a **diagnostic finding**, not a screening result. Patients with invasive cancer on cytology do NOT undergo excisional cone biopsy as a diagnostic procedure. Instead, they proceed directly to: 1. **Clinical staging** (imaging: CT/MRI pelvis, chest X-ray) 2. **Colposcopy and punch biopsy** to confirm diagnosis and assess extent 3. **Treatment planning** (surgery, radiation, chemotherapy) based on stage **Clinical Pearl:** Excisional cone biopsy (LEEP/cold knife conization) is a diagnostic AND therapeutic procedure for **precancerous lesions** (CIN1, CIN2, CIN3), NOT for invasive cancer. In invasive cancer, cone biopsy risks incomplete staging and inadequate treatment margins. ### Correct Statements Explained **Option 1 (TRUE):** ASC-US with positive HPV reflex testing has a ~30% risk of CIN2+. Colposcopy with directed biopsy is the standard management. **Option 2 (TRUE):** LSIL with negative HPV reflex has <5% risk of CIN2+. Repeat cytology at 12 months is safe and cost-effective; colposcopy is not indicated. **Option 3 (TRUE):** HSIL carries ~70% risk of CIN2+ or invasive disease. Immediate colposcopy is mandatory regardless of HPV status (HPV testing is not performed for HSIL). [cite:Park 26e Ch 23] [cite:Bethesda System 2014 for Reporting Cervical Cytology]